RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis.

RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis.
复制标题

DOI:
10.1016/j.ccell.2018.01.001
复制
发表时间:
2018-02-12
期刊:
影响因子:
50.3
通讯作者:
Palomero T
Palomero T
中科院分区:
医学1区
文献类型:
--
作者:
Cortes JR;Ambesi-Impiombato A;Couronné L;Quinn SA;Kim CS;da Silva Almeida AC;West Z;Belver L;Martin MS;Scourzic L;Bhagat G;Bernard OA;Ferrando AA;Palomero T

文献摘要

参考文献

被引文献

相似文献

血管免疫母细胞 T 细胞淋巴瘤 (AITL) 是一种源自滤泡辅助 T (Tfh) 细胞恶性转化的侵袭性肿瘤。 AITL 的特征是 10-11 易位 2 (TET2) 表观遗传肿瘤抑制基因的功能丧失突变和 RHOA 小 GTP 酶的高度复发突变 (p.Gly17Val)。然而,RHOA G17V 在 AITL 中的具体作用仍不清楚。 CD4+ T 细胞中 Rhoa G17V 的表达诱导 Tfh 细胞分化;与 ICOS 上调相关的增殖增加以及 PI3K 和 MAPK 信号传导增加。此外,RHOA G17V 表达与 Tet2 缺失一起导致小鼠出现 AITL。重要的是,Tet2−/− RHOA G17V 体内肿瘤增殖可以通过 ICOS/PI3K 特异性阻断来抑制,支持 ICOS 信号在 Tfh 细胞转化中的驱动作用。科尔特斯等人。研究表明 CD4+ T 细胞中 Rhoa G17V 的表达驱动增殖和 Tfh 极化,他们通过结合 Rhoa G17V 表达和 Tet2 缺失开发了血管免疫母细胞 T 细胞淋巴瘤模型。这些肿瘤表现出 ICOS 和 PI3K/MAPK 信号传导增加,并且对通路抑制敏感。
Angioimmunoblastic T cell lymphoma (AITL) is an aggressive tumor derived from malignant transformation of T follicular helper (Tfh) cells. AITL is characterized by loss-of-function mutations in Ten-Eleven Translocation 2 (TET2) epigenetic tumor suppressor and a highly recurrent mutation (p.Gly17Val) in the RHOA small GTPase. Yet, the specific role of RHOA G17V in AITL remains unknown. Expression of Rhoa G17V in CD4+ T cells induces Tfh cell specification; increased proliferation associated with ICOS upregulation and increased PI3K and MAPK signaling. Moreover, RHOA G17V expression together with Tet2 loss resulted in development of AITL in mice. Importantly, Tet2−/− RHOA G17V tumor proliferation in vivo can be inhibited by ICOS/PI3K-specific blockade, supporting a driving role for ICOS signaling in Tfh cell transformation. Cortes et al. show that expression of Rhoa G17V in CD4+ T cells drives proliferation and Tfh polarization, and they develop an angioimmunoblastic T cell lymphoma model by combining Rhoa G17V expression and Tet2 loss. These tumors show increased ICOS and PI3K/MAPK signaling and are sensitive to pathway inhibition.
DOI: 10.1016/j.immuni.2011.03.023
发表时间: 2011-06-24
期刊: Immunity
影响因子: 32.4
作者:
Choi YS;Kageyama R;Eto D;Escobar TC;Johnston RJ;Monticelli L;Lao C;Crotty S
通讯作者: Crotty S
DOI: 10.1084/jem.20141380
发表时间: 2015-04-06
期刊: The Journal of experimental medicine
影响因子: --
作者:
Hatzi K;Nance JP;Kroenke MA;Bothwell M;Haddad EK;Melnick A;Crotty S
通讯作者: Crotty S
DOI: 10.1073/pnas.0911573106
发表时间: 2009-12-01
影响因子: 11.1
作者:
Gigoux, Mathieu;Shang, Jijun;Suh, Woong-Kyung
通讯作者: Suh, Woong-Kyung
DOI: 10.1182/blood-2006-10-055145
发表时间: 2007-06-01
期刊: BLOOD
影响因子: 20.3
作者:
de Leval, Laurence;Rickman, David S.;Gaulard, Philippe
通讯作者: Gaulard, Philippe
DOI: 10.1158/2326-6066.cir-15-0240
发表时间: 2016-05
影响因子: 10.1
作者:
Hsu M;Sedighim S;Wang T;Antonios JP;Everson RG;Tucker AM;Du L;Emerson R;Yusko E;Sanders C;Robins HS;Yong WH;Davidson TB;Li G;Liau LM;Prins RM
通讯作者: Prins RM